8-K: Beyond Air Reports Strong Revenue Growth and Advances Key Product Pipeline with Next-Gen LungFit PH FDA Submission

Beyond Air, Inc. announced a 220% increase in fiscal year 2025 revenue, provided robust fiscal year 2026 guidance, and submitted a premarket approval supplement for its next-generation LungFit PH II device to the FDA, alongside significant international expansion and a new board appointment.

Summary

• Beyond Air, Inc. reported revenues of $3.7 million for the fiscal year ended March 31, 2025, a 220% increase compared to $1.2 million in fiscal year 2024.
• The company expects to report at least $1.7 million in revenue for the quarter ending June 30, 2025, and introduced revenue guidance of $12 million to $16 million for the full fiscal year 2026.
• A premarket approval (PMA) supplement application was submitted to the U.S. Food and Drug Administration (FDA) for LungFit PH II, the next-generation therapeutic nitric oxide generator, designed to be smaller, lighter, and transport-ready.
• Beyond Air has expanded its international distribution partnerships, now covering over 25 countries and more than 2 billion lives, with LungFit PH actively shipping to Europe, Australia, and the Middle East.
• Robert Goodman, a seasoned healthcare executive, was appointed as an independent member of the Company's Board of Directors, effective June 13, 2025.
• The net loss attributable to common stockholders for fiscal year 2025 was ($46.6) million, or ($0.69) per share, an improvement from ($60.2) million, or ($1.82) per share, in fiscal year 2024.
• Cash, cash equivalents, and marketable securities stood at $6.9 million as of March 31, 2025, excluding a $1.0 million payment received post-period end.
• The company completed a $2 million equity financing in NeuroNOS from private investors and received an additional $2.0 million financing under an existing long-term debt agreement subsequent to March 31, 2025.

Sentiment

Score: 7

Explanation: The document conveys a strong positive sentiment driven by significant revenue growth, optimistic future guidance, key product development milestones (FDA submission for LungFit PH II), and successful international expansion. While the company still reports a net loss and cash burn, the improvements in financial performance and strategic advancements outweigh the current financial challenges, indicating strong commercial momentum and future potential.

Positives

• Annual revenue for fiscal year ended March 31, 2025, increased by 220% to $3.7 million, demonstrating strong commercial momentum.
• Strong revenue guidance for fiscal year 2026 of $12 million to $16 million, indicating anticipated sustained double-digit sequential growth.
• Submission of PMA supplement for the second-generation LungFit PH II to the FDA, which is expected to unlock significant market potential due to its improved design (smaller, lighter, transport-ready).
• Significant international expansion with new distribution partnerships in over 25 countries, covering more than 2 billion lives, leading to strong initial order activity and shipments.
• Appointment of Robert Goodman, a commercially focused seasoned healthcare executive, to the Board of Directors, enhancing governance and strategic capabilities.
• Reduction in Research and Development expenses by $7.5 million and Selling, General and Administrative expenses by $11.3 million in fiscal year 2025 compared to fiscal year 2024.
• Net loss attributable to common stockholders decreased to ($46.6) million in FY25 from ($60.2) million in FY24, indicating improved financial performance.
• NeuroNOS program secured $2 million in equity financing from private investors, accelerating preclinical development for autism spectrum disorder treatments.
• U.S. Patent and Trademark Office issued a patent protecting the method of delivering gaseous nitric oxide for non-tuberculous mycobacteria (NTM) lung infection treatment.

Negatives

• Cost of revenue of $5.4 million for fiscal year 2025 exceeded revenue, primarily due to depreciation of LungFit devices and one-time upgrade costs.
• The company reported a gross loss of ($1.663) million for the fiscal year ended March 31, 2025.
• Cash burn in fiscal year 2025, excluding financing and debt extinguishment impacts, was $44.1 million.
• Cash, cash equivalents, and marketable securities were relatively low at $6.9 million as of March 31, 2025.
• Other expense increased by $2.6 million to $3.9 million, mainly due to a non-cash loss recorded upon the retirement of the Avenue Capital debt.
• A loss on disposal of fixed assets of ($738) thousand was recorded for the year ended March 31, 2025.

Risks

• The ability to raise additional capital may be challenging.
• The timing and results of future pre-clinical studies and clinical trials are uncertain.
• Regulatory authorities, including the FDA and comparable non-U.S. regulatory authorities, may not grant or may delay approval for product candidates.
• The approach to discover and develop novel drugs is unproven and may never lead to efficacious or marketable products.
• The ability to fund and the results of further pre-clinical studies and clinical trials of product candidates are not guaranteed.
• Challenges in obtaining, maintaining, and protecting intellectual property utilized by products.
• Difficulties in obtaining regulatory approval for products.
• Competition from others using similar technology and others developing products for similar uses.
• Dependence on collaborators for various aspects of business operations.

Future Outlook

Beyond Air anticipates sustained double-digit sequential revenue growth, expecting at least $1.7 million in revenue for the quarter ending June 30, 2025, and providing full fiscal year 2026 revenue guidance of $12 million to $16 million. The company believes the approval of the second-generation LungFit PH II system will unlock significant market potential and, coupled with global expansion and rising brand recognition, marks an exciting and pivotal year for the company and its shareholders. Future milestones include ongoing FDA review for the cardiac surgery PMA supplement, continued clinical development for the Beyond Cancer solid tumor program, and preclinical development for the NeuroNOS ASD program.

Management Comments

• "Our commercial momentum is building, and that progress is now being reflected in our topline results."
• "With LungFit PH now installed and in regular use at more than 45 hospitals nationwide, awareness is accelerating. Clinicians and administrators are increasingly recognizing the advantages of our cylinder-free system compared to conventional nitric oxide delivery methods."
• "Regulatory approvals and new international partnerships across Europe, the Middle East, and Asia have already driven strong order activity, with over a dozen initial units shipped to customers in just the past few weeks."
• "We expect to report at least $1.7 million in revenue for the quarter ending June 30, 2025, and anticipate sustained double-digit sequential revenue growth moving forward, leading to FY 2026 revenues expected to be in the range of $12 to $16 million."
• "The submission of the PMA supplement to the FDA for our second-generation LungFit PH device, which we announced yesterday, could be transformative for our business."
• "If approved, we believe this new system will unlock significant market potential. Coupled with our global expansion and rising brand recognition, we are entering what we believe will be an exciting and pivotal year for Beyond Air and our shareholders."
• "We are pleased to announce that development of our transport-ready LungFit PH II has resulted in a NO system which we believe is far superior to legacy systems currently available in the market."
• "While our first-generation system already delivers key advantages to hospitals, this next-generation device raises the bar with a reduced weight and footprint, simplified operation, longer service interval, and full compatibility with both air and ground transport. It also includes an automated backup system that retains most primary system capabilities."
• "Once approved, we are confident that the introduction of LungFit PH II will play a pivotal role in accelerating our market expansion and advancing our position as a global leader in hospital-based NO delivery."

Industry Context

Beyond Air operates in the medical device and biopharmaceutical sectors, specifically focusing on nitric oxide (NO) therapies. The company's LungFit PH system aims to disrupt the conventional nitric oxide delivery market by offering a cylinder-free, on-demand solution, addressing logistical and safety challenges associated with traditional high-pressure NO cylinders. This innovation positions Beyond Air to potentially gain market share in the treatment of hypoxic respiratory failure in neonates (PPHN) and expand into other indications like severe lung infections and cardiac surgery. The development of a transport-ready device (LungFit PH II) aligns with the industry trend towards more portable and versatile medical equipment. Furthermore, the company's pipeline in oncology (Beyond Cancer) and neurological disorders (NeuroNOS) indicates a broader strategic ambition to leverage nitric oxide's therapeutic potential across diverse medical fields, competing with established players and emerging biotechs in these areas.

Comparison to Industry Standards

• Beyond Air's LungFit PH system is positioned as a superior alternative to 'legacy systems' and 'conventional nitric oxide delivery methods' by eliminating large, high-pressure NO cylinders, which are the current industry standard. This offers advantages in reducing inventory/storage, improving safety by eliminating NO2 purging steps, and providing operational benefits.
• The LungFit PH II, if approved, is expected to be 'far superior to legacy systems currently available in the market' due to its reduced weight, footprint, simplified operation, longer service interval, and full compatibility with air and ground transport, along with an automated backup system. This directly targets the limitations of existing NO delivery systems.
• The company highlights that 'currently no FDA approved nitric oxide delivery system is labeled for cardiac surgery' in the U.S., indicating a potential first-mover advantage if their cardiac surgery PMA supplement is approved, setting a new standard for this specific application.
• For PPHN, low concentration inhaled NO therapy has been the standard-of-care for over 20 years in the United States, and Beyond Air's LungFit PH system is designed to deliver NO doses consistent with this standard (20 ppm NO, with a range of 0.5 ppm 80 ppm).

Management Changes

Corporate Governance

Stakeholder Impact

• **Shareholders:** Potential for increased shareholder value due to significant revenue growth, positive future guidance, and advancements in the product pipeline. The reduction in net loss and new financing could also be viewed positively, though continued cash burn remains a factor.
• **Customers (Hospitals/Clinicians):** Introduction of LungFit PH II offers a more advanced, portable, and efficient nitric oxide delivery system, potentially improving patient care and operational efficiency in hospitals.
• **Employees:** Continued commercial momentum and pipeline development suggest stability and potential growth opportunities within the company.
• **Partners (International Distributors):** Expansion of distribution agreements and active shipments indicate strengthening partnerships and broader market reach.
• **Creditors:** The company has $12.2 million in long-term debt, with repayment not beginning until October 2026, and has secured additional financing, which may provide some comfort regarding short-term liquidity, but cash burn remains a consideration.

Next Steps

• Continue commercial activities to drive demand for LungFit PH in the U.S. and internationally.
• Await FDA review and potential approval of the PMA supplement for LungFit PH II.
• Continue the ongoing FDA review for the cardiac surgery PMA supplement.
• Continue Phase 1a trial for Beyond Cancer's solid tumor program (50,000 ppm dose ongoing).
• Review timing for study initiation of Phase 1b trial (combination therapy) for Beyond Cancer in Israel.
• Accelerate preclinical development of NeuroNOS's small-molecule drug for autism.
• Continue to expand international distribution agreements and shipments.

Key Dates

Recommendation

Keywords

Nitric Oxide, Medical Device, Biopharmaceutical, LungFit PH, FDA Approval, PMA Supplement, Respiratory Failure, PPHN, Hypoxic Respiratory Failure, NTM Infection, Autism Spectrum Disorder, Solid Tumors, Commercial Stage, Healthcare Executive, International Distribution, Financial Results, Revenue Growth, Nasdaq, XAIR